NEW YORK (GenomeWeb) – Claritas Genomics said today that it will use NextCode Health's integrated and clinical research platform to analyze and interpret its next-generation sequencing-based clinical diagnostic tests.
Claritas, which is based in Cambridge, Mass., and is affiliated with Boston Children's Hospital, offers around 110 genetic tests, many of them single-gene Sanger-based tests. It also offers the NGS-based ClariFocus Exome for Pediatric Neurology as well as NGS panels for muscular dystrophy and nephrotic syndrome. The CLIA-certified and CAP-accredited laboratory also won a $9 million contract last year to sequence the exomes of veteran samples.
Claritas said that NextCode's platform will enable it to speed delivery of test results.
"NextCode's system supports identification of known mutations, enables us to rapidly home in on novel ones, and visualize them on screen, linking the sequencing information to our information on the child's clinical condition," Claritas CEO Patrice Milos said in a statement.
Jeffrey Gulcher, president and chief scientific officer of NextCode, added that Claritas' use of NextCode's platform will enable physicians to deliver "diagnoses and expert interpretation using raw sequence data in real time," as well as to advance research and turn "new findings into benefits for patients in the clinic."